EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial

Yingtan Wang, Zhe Lu, Guanglei Xun

Journal of Affective Disorders · 2024

DOI: 10.1016/j.jad.2023.10.038 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2024. Verfasst von Yingtan Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical U…. Hauptthemen laut MEDLINE: Escitalopram, Major Depressive Disorder. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To explore the effect of escitalopram combined with aripiprazole on cognitive function in patients with major depressive disorder (MDD), and to evaluate the clinical efficacy of the combination therapy. METHOD: A total of 70 patients with first-episode MDD were randomly divided into the study group or the control group, receiving escitalopram combined with aripiprazole (5 mg/day) or escitalopram monotherapy respectively for 8 weeks. The severity of illness was assessed by using the Hamilton Rating Scale for Depression (HAMD) at baseline, at the end of 4th and 8th week, and cognitive function was assessed by using the THINC integrated tool (THINC-it), the Wisconsin Card Sorting Test (WCST), and the Continuous Performance Test (CPT). Rating Scale for Extrapyramidal Side Effects (RSESE) was applied to assess adverse reactions. RESULTS: The average HAMD-17 and HAMA scores decreased over time in both the control and the study groups, but the reductions were not statistically different between two groups with the passage of time. In WCST, total number of response (TR) of the study group decreased relative to the baseline at the end of the eighth week, but the control group did not significantly change during whole eight weeks. Perseverative errors (PE) in the control group eventually decreased at the end of Week 8 compared to that at Week 4, but in the study group, it was a continuous trend of decrease. In CPT, the decrease of leakage responses (LR) in the study group was higher than that of the control group in 2-digit number, and LR of the control group was higher than that of the study group at the end of Week 8 in 4-digit number. The downtrend of LR in 4-digit number kept for the whole period in study group, while in the control group, the LR did not decrease significantly until the end of Week 8 compared to that at baseline. CONCLUSION: Escitalopram combined with a low-dose of aripiprazole, and escitalopram monotherapy could both enhance cognitive function of MDD patients, while the improvements of combination therapy might happen relatively earlier. The combined use of escitalopram and aripiprazole might be more beneficial to the domains of executive function (EF) and continuous attention compared to escitalopram monotherapy. There was no significant differences between two treatment options in alleviating depressive and anxiety symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EscitalopramMajor Depressive DisorderHumansAripiprazoleAntidepressive AgentsDepressionTreatment OutcomeCognitionCitalopramDouble-Blind Method

Stichwörter der Autor:innen

AripiprazoleCognitive functionEscitalopramMajor Depressive Disorder

Substanzen

AripiprazoleEscitalopramAntidepressive AgentsCitalopram

Autor:innen und Institutionen

  • The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China; Department of Mental Health, Jining Medical…
  • Peking University Sixth Hospital, Peking University Institute of Mental Health, Beijing, China.
  • Shandong Mental Health Center, Shandong University, Jinan, China. Electronic address: xungl2019@163.com.

Zitieren

APA

Wang, Y., Lu, Z., & Xun, G. (2024). Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2023.10.038

Vancouver

Wang Y, Lu Z, Xun G. Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial. Journal of Affective Disorders. 2024. doi:10.1016/j.jad.2023.10.038

BibTeX
@article{Wang2024,
  author = {Wang, Yingtan and Lu, Zhe and Xun, Guanglei},
  title = {Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial},
  journal = {Journal of Affective Disorders},
  year = {2024},
  doi = {10.1016/j.jad.2023.10.038}
}
Kostenlos starten →